Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 10;11(3):371.
doi: 10.3390/antibiotics11030371.

Facing the Increased Prevalence of Antibiotic-Resistant M. tuberculosis: Exploring the Feasibility of Realising Koch's Aspiration of Immunotherapy of Tuberculosis

Peter A Bretscher  1
Affiliations

Facing the Increased Prevalence of Antibiotic-Resistant M. tuberculosis: Exploring the Feasibility of Realising Koch's Aspiration of Immunotherapy of Tuberculosis

Peter A Bretscher. Antibiotics (Basel). .

Abstract

Koch attempted to treat tuberculosis in the late 1800s by administering an antigenic extract derived from the pathogen to patients. He hoped to bolster the patient's protective immunity. The treatment had diverse results. In some, it improved the patient's condition and in others led to a worsening state and even to death. Koch stopped giving his experimental treatment. I consider here three issues pertinent to realizing Koch's vision. Rational immunotherapy requires a knowledge of what constitutes protective immunity; secondly, how on-going immune responses are regulated, so the patient's immunity can be modulated to become optimally protective; thirdly, a simple methodology by which treatment might be realized. I deliberately cast my account in simple terms to transcend barriers due to specialization. The proposed immunotherapeutic treatment, if realizable, would significantly contribute to overcoming problems of treatment posed by antibiotic resistance of the pathogen.

Keywords: host-targeted therapies; immunotherapy; tuberculosis.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
Dependence of cell-mediated/IgG antibody nature of response on dose of antigen and time after antigen impact.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Nunes-Alves C., Booty M.G., Carpenter S.M., Jayaraman P., Rothchild A.C., Behar S.M. In search of a new paradigm for protective immunity to TB. Nat. Rev. Microbiol. 2014;12:289–299. doi: 10.1038/nrmicro3230. - DOI - PMC - PubMed
    1. Surcel H.M., Troye-Blomberg M., Paulie S., Andersson G., Moreno C., Pasvol G., Ivanyi J. Th1/Th2 profiles in tuberculosis, based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens. Immunology. 1994;81:171–176. - PMC - PubMed
    1. Menon J., Hoeppner V.H., Judd A., Power C.A., Bretscher P.A. A hypothesis for the existence of two types of tuberculosis, reflecting two distinct types of immune failure to control the pathogen, based upon prevalence of mycobacterium-specific IgG subclasses. Scand. J. Immunol. 2018;87:e12665. doi: 10.1111/sji.12665. - DOI - PubMed
    1. Lenzini L., Rottoli P., Rottoli L. The spectrum of human tuberculosis. Clin. Exp. Immunol. 1977;27:230–237. - PMC - PubMed
    1. Buddle B.M., de Lisle G.W., Pfeffer A., Aldwell F.E. Immunological responses and protection against Mycobacterium bovis in calves vaccinated with a low dose of BCG. Vaccine. 1995;13:1123–1130. doi: 10.1016/0264-410X(94)00055-R. - DOI - PubMed

LinkOut - more resources